As seen online:
“The Delphi consensus survey highlighted several unmet needs in the management of patients with HC, particularly the high burden of phlebotomy treatment and its limitations especially in controlling common symptoms like fatigue and arthralgia. Respondents indicated a substantial unmet need among patients who experience high treatment burden or who poorly tolerate phlebotomy and identified molecular-targeted therapies that address the pathophysiological root cause of HC as a suitable therapeutic option for this subgroup of patients.”
— from Delphi expert consensus on phlebotomy limitations and treatment challenges in HFE-related hemochromatosis | Published in Clinical Hematology International as of 2 September 2026